Heather Scharpenseel

Heather Scharpenseel

Auto-generated profile, based on publicly available information

Heather Scharpenseel

Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
FJFelix John
Felix John
LRLea Ruge
Lea Ruge
MVMalte Verheyen
Malte Verheyen
HSHeather Scharpenseel
Heather Scharpenseel
SMSebastian Yves Friedrich Michels
Sebastian Yves Friedrich Michels
MSMatthias Scheffler
Matthias Scheffler
Purpose: KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood. Experimental Design: In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed. Results: The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months. Conclusions: KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.

10 June 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
LRLea Ruge
Lea Ruge
FJFelix John
Felix John
MVMalte Verheyen
Malte Verheyen
RRRichard Riedel
Richard Riedel
SMSebastian Michels
Sebastian Michels
MSMatthias Scheffler
Matthias Scheffler
Purpose: KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for approximately 1% to 7% of all KRAS mutations in non–small cell lung cancer (NSCLC). So far, the prognostic value of this cohort and its response to different treatment regimens remain unclear. Experimental Design: Between 2011 and 2023, diagnostic samples from patients with NSCLC were analyzed using next-generation sequencing. Molecular data were correlated with clinical records, and time-to-event analyses were performed using the Kaplan–Meier estimate. Results: Of the 8,862 analyzed probes, we identified 487 (5.5%) patients with KRAS Q61 mutations and further analyzed 365 patients. Most presented with Q61H (74.0%) and Q61L (20.8%) mutations that demonstrated distinct patterns in smoking history (7% vs. 3.3% never smokers, respectively) and co-mutational landscape. The most frequent co-mutations in Q61H were STK11 (45.8%), TP53 (32.1%), and KEAP1 (31.3%), whereas Q61L was mutually exclusive to STK11 and had a lower incidence of co-occurring KEAP1 mutations (11.5%). The median overall survival for the entire cohort was 12.3 months, with a favorable survival of 22.1 and 65.4 months for patients receiving combined chemoimmunotherapy and immunotherapy as first-line treatment, respectively. Real-world progression-free survival was significantly prolonged in patients receiving immunotherapy, either as monotherapy or combined therapy, versus chemotherapy (CTX) in the first-line setting (P < 0.01). Conclusions: KRAS Q61H and Q61L were the predominant mutational subtypes and demonstrated distinct molecular and clinical characteristics, with differences in the co-mutational landscape contributing to the observed survival differences between subtypes. Immunotherapy-based regimens were associated with more favorable outcomes compared with CTX, particularly in patients with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%), underscoring the importance of subtype-specific molecular characterization in clinical decision-making. See related commentary by Meazza Prina and Mezquita, p. 5014


3 November 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
LNLucia Nogova
Lucia Nogova
FMFlorian Malchers
Florian Malchers
Axel HillmerAxel Hillmer
Axel Hillmer
ITInken Terjung
Inken Terjung
HSHeather Scharpenseel
Heather Scharpenseel
JWJürgen Wolf
Jürgen Wolf
Purpose: FGFR alterations occur in approximately 2% of patients with non–small cell lung cancer (NSCLC), predominantly in squamous cell histology (sqNSCLC). We evaluated the efficacy of the selective FGFR1–4 inhibitor erdafitinib in patients with FGFR-altered NSCLC. Patients and Methods: Patients with NSCLC were prescreened within the national Network Genomic Medicine (nNGM) for FGFR mutations/fusions. Patients were treated with erdafitinib after assessment of every alteration in the study-specific molecular board in three cohorts: (i) high-confidence activating FGFR fusions, (ii) high-confidence activating FGFR mutations, and (iii) low-confidence activating FGFR alterations. The primary objective was the best confirmed overall response rate on erdafitinib in cohorts 1 and 2 assessed by RECIST 1.1 every 8 weeks. Statistical analysis was based on the Simon two-stage minimax design. Results: Between July 2019 and September 2022, 44,537 patients were prescreened in nNGM, 26 patients were enrolled in stage I of the Simon design, and 4 patients failed screening. Most patients were male (77%) and had sqNSCLC (73%). All patients were current or previous smokers. Of 22 patients on erdafitinib, 7 were treated in cohort 1, 8 were treated in cohort 2, and 7 were treated in cohort 3. In cohort 1, 2 of 7 patients achieved partial response (PR). However, one PR remained unconfirmed. The best response in cohort 2 was stable disease. The most observed adverse events of any grade were hyperphosphatemia (in 45.5%) and diarrhea and dry mouth (both in 31.8% of patients). Conclusions: According to the first stage of the two-stage Simon design, erdafitinib showed preliminary efficacy in NSCLC with FGFR fusions. Further molecular and clinical data are needed to evaluate the efficacy of FGFR inhibition in NSCLC, especially in patients with FGFR mutations.

17 June 2026
Verified
Other
Open access
FJFelix John
Felix John
LRLea Ruge
Lea Ruge
MVMalte Verheyen
Malte Verheyen
HSHeather Scharpenseel
Heather Scharpenseel
SMSebastian Yves Friedrich Michels
Sebastian Yves Friedrich Michels
MSMatthias Scheffler
Matthias Scheffler
Supplementary Figure S2: Kaplan-Meier statistics on median real-world overall survival (rwOS) in different subgroups

11 August 2026 in Clinical Lung Cancer
Verified
Journal Article
Open access
RRRichard Riedel
Richard Riedel
MVMalte Verheyen
Malte Verheyen
SMSebastian Michels
Sebastian Michels
LRLea Ruge
Lea Ruge
SSSofia Stilianakis
Sofia Stilianakis
FJFelix John
Felix John
Small-cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis and limited therapeutic progress over recent decades. Although PD-L1 inhibitors have modestly improved survival, responses are not durable. There are no predictive biomarkers that would allow for a personalized treatment strategy. Targeting DNA damage repair deficiencies represents a promising treatment strategy in various solid tumors. Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib have demonstrated efficacy in homologous recombination deficiency (HRD)-positive tumors, and preclinical data suggest synergistic activity with immune checkpoint blockade. GUIDANCE is a biomarker-driven, multicenter, single-arm, open-label phase II trial evaluating maintenance therapy with durvalumab and olaparib in patients with advanced or metastatic SCLC without progression after first-line therapy with platinum, etoposide and durvalumab. Patients are prospectively selected for HRD based on homologous recombination repair gene alterations and/or a genomic instability score. Following central prescreening, 29 patients will be enrolled. Patients receive durvalumab (1500 mg every 4 weeks) and olaparib (300 mg twice daily) until progression or unacceptable toxicity. The primary endpoint is progression-free survival (PFS) by RECIST 1.1. Secondary endpoints are overall survival, safety and tolerability. Exploratory analyses include circulating tumor DNA (ctDNA) monitoring of individual TP53 mutations, assessment of SLFN11 expression, and characterization of immune cell composition via multiplex immunohistochemistry. This trial investigates a chemotherapy-free, genomically stratified maintenance strategy targeting both DNA damage repair deficiency and immune evasion in SCLC. By integrating HRD-based patient selection with concurrent PARP and immune checkpoint inhibition, GUIDANCE aims to establish a more individualized therapeutic approach and to generate a signal for further evaluation in biomarker-defined patient populations. Trial registration number EuraCT 2024-512373-27-00.